Sarah Rohde long had an interest in treating cancer, and her research during her undergraduate and medical school years at the University of Virginia underscored that. What she didn’t expect was to become a surgeon.
Patient ambassador Lily Hensiek, center, served as Mayor of Smashville at the Nashville Predators Hockey Fights Cancer Night on Saturday, Nov. 3.
Vanderbilt researchers are developing new approaches to study the mechanisms underlying why breast cancer cells home to bone and lie dormant, evading treatment.
Vanderbilt researchers have characterized the functional transfer of long RNAs between colorectal cancer cells — a form of cell-cell communication that may contribute to cancer aggressiveness.
Patients with stage IV small-cell lung cancer lived longer when given the immunotherapy atezolizumab with chemotherapy, setting the stage for what could become the first new treatment approved in decades for this particularly aggressive form of lung cancer.
Vanderbilt chemists have been awarded $7.2 million over the next five years from the National Cancer Institute to lead an initiative to better understand how a combination chemotherapy for breast cancer targets DNA.